Long Term Follow-Up for RGX-111

Plain-language summary

This is a long-term follow-up study for people who previously received the gene therapy RGX-111 in an earlier trial. No new treatment is given; the goal is to monitor the long-term health of those who received the therapy. Participants who received RGX-111 in the parent trial may join. It is a non-phase follow-up study enrolling by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

REGENXBIO Inc.

Intervention

No Intervention

Start date

7/24/2023

Estimated completion

9/1/2027

Countries

United States, Brazil

Related genes

Locations

• Orange, United States
• Porto Alegre, Brazil

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* To be eligible, a participant must have previously received RGX-111 in a separate parent trial.
* Participant or participant's legal guardian(s) is/(are) willing and able to provide written, signed informed consent.

Exclusion Criteria:

* None.